Literature DB >> 12944998

Canadian guidelines for the management of acute exacerbations of chronic bronchitis.

Meyer S Balter1, Jacques La Forge, Donald E Low, Lionel Mandell, Ronald F Grossman.   

Abstract

Acute exacerbations of chronic bronchitis (AECB) account for over 1.5 million physician visits annually in Canada and are a cause of significant morbidity and mortality. This document represents a joint effort between respirologists, microbiologists, infectious disease specialists and family physicians to update the Canadian AECB guidelines published in 1994. Treatment recommendations are graded on the strength of evidence in the published literature where possible. The role for oral corticosteroid therapy in preventing treatment failures, speeding up recovery and delaying the time to next exacerbation is discussed. Risk factors for treatment failure were used to stratify patients into risk groups to help guide antibiotic treatment recommendations. The importance of emerging antimicrobial resistance to current antibiotics is reviewed and strategies to prevent future AECB episodes are suggested.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12944998     DOI: 10.1155/2003/486285

Source DB:  PubMed          Journal:  Can Respir J        ISSN: 1198-2241            Impact factor:   2.409


  25 in total

Review 1.  Amoxicillin/clavulanic acid 2000mg/125mg extended release (XR): a review of its use in the treatment of respiratory tract infections in adults.

Authors:  Paul L McCormack; Gillian M Keating
Journal:  Drugs       Date:  2005       Impact factor: 9.546

2.  Antibiotics in acute exacerbations of chronic obstructive pulmonary disease.

Authors:  R Andrew McIvor
Journal:  Can Fam Physician       Date:  2009-01       Impact factor: 3.275

3.  Real-life treatment of acute exacerbations of chronic bronchitis with moxifloxacin or macrolides: a comparative post-marketing surveillance study in general practice.

Authors:  T Schaberg; M Möller; T File; K Stauch; H Landen
Journal:  Clin Drug Investig       Date:  2006       Impact factor: 2.859

4.  Pharmacokinetics of ciprofloxacin and its penetration into bronchial secretions of mechanically ventilated patients with chronic obstructive pulmonary disease.

Authors:  Paschalina Kontou; Kalliopi Chatzika; Georgia Pitsiou; Ioannis Stanopoulos; Paraskevi Argyropoulou-Pataka; Ioannis Kioumis
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

5.  Previous outpatient antibiotic use in patients admitted to hospital for COPD exacerbations: room for improvement.

Authors:  M Miravitlles; J J Soler-Cataluña; F Baranda; P Cordero; J-V Greses; C de la Roza
Journal:  Infection       Date:  2012-08-21       Impact factor: 3.553

6.  Clinical efficacy of farcosolvin syrup (ambroxol-theophylline-guaiphenesin mixture) in the treatment of acute exacerbation of chronic bronchitis.

Authors:  Mostafa Yakoot; Amel Salem; Abdel-Mohsen Omar
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2010-08-09

7.  Prulifloxacin.

Authors:  Susan J Keam; Caroline M Perry
Journal:  Drugs       Date:  2004       Impact factor: 9.546

Review 8.  Role of macrolide therapy in chronic obstructive pulmonary disease.

Authors:  Fernando J Martinez; Jeffrey L Curtis; Richard Albert
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 9.  Newer fluoroquinolones in the treatment of acute exacerbations of COPD.

Authors:  Amit Patel; Robert Wilson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 10.  Fixed combination therapies in COPD--effect on quality of life.

Authors:  Beatrix Groneberg-Kloft; Axel Fischer; Tobias Welte
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.